Nu Skin Enterprises (NUS)
NYSE:NUS
Want to see NUS full AI Analyst Report?
Top Page
Nu Skin
(NYSE:NUS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$6.00
▼(-42.36% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by mixed financial performance: improved balance-sheet leverage and a return to positive profitability, but persistent revenue contraction and weak cash conversion. Technicals are a meaningful negative with the stock trading below major moving averages and weak momentum. Valuation remains a constraint due to a high P/E despite a supportive dividend yield, while the earnings call adds modest support via maintained guidance and expected sequential improvement tempered by ongoing margin pressure.
Positive Factors
Improved leverage and liquidity
Reduced leverage and a stronger balance sheet lower refinancing risk and increase strategic optionality. With multi-year credit extended and sizable equity, the company can fund investments, buybacks, and product rollouts without forcing distress sales or aggressive asset cuts, supporting stability over months.
Negative Factors
Persistent revenue contraction
Multi-year top-line decline erodes distributor economics and scale benefits, pressuring unit economics and fixed-cost absorption. Continued revenue shrinkage diminishes long-term earnings power and makes sustainable margin recovery and investment funding harder without reversing underlying demand trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage and liquidity
Reduced leverage and a stronger balance sheet lower refinancing risk and increase strategic optionality. With multi-year credit extended and sizable equity, the company can fund investments, buybacks, and product rollouts without forcing distress sales or aggressive asset cuts, supporting stability over months.
Read all positive factors
Nu Skin Key Performance Indicators (KPIs)
Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.51M
Dividend Yield2.39%
Average Volume (3M)494.37K
Price to Earnings (P/E)47.8
Beta (1Y)1.24
Revenue Growth-14.17%
EPS GrowthN/A
CountryUS
Employees3,100
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.12
Shares Outstanding48,550,545
10 Day Avg. Volume707,612
30 Day Avg. Volume494,373
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.32
P/FCF Ratio10.31
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.36
Enterprise Value/Ebitda2.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1
Revenue Forecast (FY)$1.43B
Nu Skin Business Overview & Revenue Model
Company Description
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and clean...
How the Company Makes Money
Nu Skin primarily makes money by selling its products through a direct-selling (multi-level) distribution model. Revenue is recognized from product sales to customers and to independent brand partners/distributors (often referred to as “sales lead...
Nu Skin Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful early strategic progress (Prysm iO data scale, subscription growth, LifePak +10% growth, regional momentum, and a strengthened balance sheet) against near-term profitability pressures (operating margin decline, higher selling expense, macro and transition costs). Management maintained guidance, signaled sequential improvement for Q2, and emphasized disciplined execution while investing in long-term growth initiatives.Positive Updates
Revenue in Line with Guidance
Q1 revenue of $320.6 million was within guidance, including a 1% favorable foreign currency impact, and management maintained full-year guidance with more clarity expected after Q2.
Negative Updates
Operating Margin Decline
Adjusted operating margin fell to 3.6% from 6.4% a year ago, a decline of 280 basis points, reflecting continued investment in strategic priorities and cost structure pressures.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue in Line with Guidance
Q1 revenue of $320.6 million was within guidance, including a 1% favorable foreign currency impact, and management maintained full-year guidance with more clarity expected after Q2.
Read all positive updates
Company Guidance
Nu Skin reiterated its full‑year guidance and set Q2 targets of $330–360 million in revenue and $0.15–0.25 in EPS (assuming relatively neutral FX), up sequentially from Q1 revenue of $320.6M (1% favorable FX) with GAAP EPS $0.04 and adjusted EPS $0.14; Q1 adjusted gross margin was 67.9% (core Nu Skin 76.9%, +20 bps YoY), adjusted operating margin was 3.6% (down from 6.4% LY), consolidated selling expense was 34.3% of revenue (vs 32.5% LY) with core selling expense at ~40.5% (management expects core selling expense to remain around 40%), G&A was 29.9% of revenue (vs 28.9% LY) but declined $9M YoY on an adjusted basis, and the company returned ~$8M to shareholders in the quarter ($3M dividends, $5M repurchases) with $137.3M remaining repurchase authorization after refinancing credit facilities through 2031; management said it will maintain the annual guide, continue investing in Prysm iO and emerging markets, and provide more clarity after Q2.Nu Skin Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
64
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.49B | 1.73B | 1.97B | 2.23B | 2.70B |
| Gross Profit | 998.90M | 1.03B | 1.18B | 1.36B | 1.59B | 2.02B |
| EBITDA | 129.58M | 143.14M | -78.83M | 202.98M | 174.97M | 368.48M |
| Net Income | 54.52M | 160.20M | -146.59M | 8.60M | 104.78M | 147.27M |
Balance Sheet | ||||||
| Total Assets | 1.38B | 1.41B | 1.47B | 1.81B | 1.82B | 1.91B |
| Cash, Cash Equivalents and Short-Term Investments | 200.41M | 239.84M | 197.99M | 267.82M | 278.51M | 354.81M |
| Total Debt | 277.61M | 364.25M | 478.23M | 607.33M | 520.52M | 503.79M |
| Total Liabilities | 582.71M | 600.07M | 817.46M | 984.50M | 923.67M | 993.71M |
| Stockholders Equity | 794.09M | 805.24M | 651.46M | 821.97M | 897.30M | 912.77M |
Cash Flow | ||||||
| Free Cash Flow | 41.57M | 46.01M | 70.16M | 60.15M | 49.01M | 72.97M |
| Operating Cash Flow | 75.98M | 80.29M | 111.74M | 118.64M | 108.06M | 141.58M |
| Investing Cash Flow | -25.17M | 170.66M | -37.96M | -134.50M | -67.08M | -88.73M |
| Financing Cash Flow | -56.51M | -202.40M | -133.18M | 10.73M | -99.50M | -104.70M |
Nu Skin Technical Analysis
Negative
10.41
Price Trends
7.20
Negative
8.43
Negative
9.56
Negative
Market Momentum
-0.42
Positive
22.04
Positive
0.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 10.41 is above the 20-day moving average (MA) of 6.91, above the 50-day MA of 7.20, and above the 200-day MA of 9.56, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 22.04 is Positive, neither overbought nor oversold. The STOCH value of 0.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nu Skin Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $3.24B | 28.63 | 10.75% | ― | 16.73% | 3.11% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | $284.51M | 47.78 | 6.84% | 2.39% | -14.17% | ― | |
54 Neutral | $29.04B | 73.12 | -6.29% | 1.30% | 0.71% | 71.47% | |
52 Neutral | $1.77B | ― | -15.12% | ― | -3.57% | -32.30% | |
47 Neutral | $743.75M | -23.40 | -4.17% | 3.51% | -5.30% | -196.78% | |
45 Neutral | $78.49M | -4.31 | -9.41% | ― | -8.16% | 85.14% |
* Consumer Defensive Sector Average
NUS
Nu Skin
5.70
-1.70
-22.99%
EL
The Estée Lauder Companies
76.14
11.10
17.06%
COTY
Coty
1.93
-3.12
-61.78%
EPC
Edgewell Personal Care
16.00
-11.60
-42.02%
ELF
e.l.f. Beauty
52.98
-28.53
-35.00%
SKIN
Beauty Health
0.66
-1.03
-60.83%
Nu Skin Corporate Events
Business Operations and StrategyExecutive/Board Changes
Nu Skin Executive Product Chief Transitions to Advisory Role
Neutral
May 8, 2026
On May 6, 2026, Nu Skin announced that Steven K. Hatchett would resign as Executive Vice President and Chief Product Officer, effective May 8, 2026, citing family health circumstances. The company noted that Hatchett will remain with Nu Skin as a ...
Business Operations and StrategyPrivate Placements and Financing
Nu Skin Secures New Five-Year Credit Facilities Agreement
Neutral
Mar 27, 2026
On March 27, 2026, Nu Skin Enterprises, Inc. entered into a Second Amended and Restated Credit Agreement that replaces its June 14, 2022 facility, securing a $175 million five-year term loan and a $75 million five-year revolving credit facility. T...
Business Operations and StrategyExecutive/Board Changes
Nu Skin Names Chelsea Lantz Interim Chief Financial Officer
Positive
Mar 20, 2026
On March 17, 2026, longtime Nu Skin Executive Vice President and CFO James D. Thomas resigned to pursue an external opportunity, and the board named Vice President and Corporate Controller Chelsea K. Lantz as interim CFO, effective March 18, 2026....
Business Operations and StrategyExecutive/Board Changes
Nu Skin Names Chayce Clark Chief Operating Officer
Positive
Mar 9, 2026
On March 5, 2026, Nu Skin’s board appointed longtime legal executive Chayce D. Clark as executive vice president, chief operating officer and chief legal officer, a move formalized in a March 9, 2026 announcement. Clark, who joined the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.